Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

1. Rugo, H.S.
2. Lerebours, F.
3. Ciruelos, E.
4. Drullinsky, P.
5. Ruiz-Borrego, M.
6. Neven, P.
7. Park, Y.H.
8. Prat, A.
9. Bachelot, T.
10. Juric, D.
11. Turner, N.
12. Sophos, N.
13. Zarate, J.P.
14. Arce, C.
15. Shen, Y.-M.
16. Turner, S.
17. Kanakamedala, H.
18. Hsu, W.-C.
19. Chia, S.